Acadia Pharmaceuticals IncACAD
Price$20.15Intrinsic value$20.813% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.1B+18.9% YoYTTM through 30 Jun 2026
Net Income $380.5M+68.0% YoYTTM through 30 Jun 2026
Free Cash Flow $145.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin90.8%
EBITDA Margin7.6%
Operating Margin-1.7%
Net Margin33.4%

Returns

30.1%ROE
23.4%ROA
41.3%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.39x
Net Debt-$851.4Mnet cash position
Cash & Equivalents$385M

Quality Metrics

Altman Z-Score6.24
Piotroski F-Score4 / 9
FCF Margin12.8%
Rule of 4024.5
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $1.1B
Diluted EPS$2.23TTM
'12'20'21'22'23'24'25
FY2025: $2.30

Dividend

No dividend

Capital Allocation

R&D Spend$331M
Capex Intensity1.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.